Universitat Autònoma de Barcelona

Impact of an early postnatal administration of an energetic supplement on growth performance, behaviour and gut microbiota in piglets with different birth weight classes

Piglets are born with limited energy reserves, and early energy supplementation may improve their growth. This study evaluated the efficacy of an early energetic supplement on growth, mortality, behaviour and gut microbiota (GM). Twenty-two sows and their litters (12.9 ± 0.3 pigl...

The first 72 hours of acute pancreatitis: patterns of variability in early clinical decision-making

To assess real-world adherence to evidence-based international guidelines in the early management of acute pancreatitis (AP), and to identify how variability in clinical decision-making is distributed during the first 72 h of care. This multicentre, cross-sectional survey was con...

Therapeutic management of axial spondyloarthritis: summary of 2024 update of the Spanish clinical practice guideline (ESPOGUIA)

Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic disease associated with significant morbidity and impaired quality of life. Rapid advances in diagnosis, monitoring, and especially treatment over the past decade have increased the complexity of axSpA management...

Genetic Testing After Heart Transplantation Uncovers Heritable Disease and Drives Family Screening

BACKGROUND: Genetic testing (GT) is established in ambulatory cardiomyopathy (CM), but its utility after heart transplantation (HTx) recipients remains poorly characterized. OBJECTIVES: This study aimed to evaluate the clinical utility of GT in adult HTx recipients with CM, focus...

Treatment-free remission after bosutinib discontinuation (BOSUTFR): results from a multicenter real-world study by the Spanish CML group

Treatment-free remission (TFR) is an established therapeutic goal for patients with chronic myeloid leukemia (CML) achieving sustained deep molecular response (DMR) on tyrosine kinase inhibitors (TKIs). However, evidence on TFR following bosutinib discontinuation remains limited....

Brentuximab Vedotin in Severe Systemic Sclerosis: Data on Long-Term Follow-Up and Retreatment

Objectives We previously reported skin and forced vital capacity (FVC) improvements in an open-label clinical trial exploring the use of brentuximab vedotin (BV) in patients with severe diffuse cutaneous systemic sclerosis (dcSSc).[1] Long-term outcomes after therapy was disconti...

High-throughput engineering of bispecific antibodies to enhance macrophage-mediated cytotoxicity of B-cell lymphoma

Abstract Macrophages are critical effectors of antibody therapies for lymphoma, but the best targets to engage their function remain unknown. Here, we develop a ‘tactical surfaceome profiling’ strategy to define a comprehensive repertoire of surface antigens on B-cell lymphoma th...

Discontools supplement Mycoplasma hyopneumoniae infections in pigs: update and knowledge gaps

This manuscript reviews current knowledge on Mycoplasma hyopneumoniae , the primary agent of enzootic pneumonia in pigs, integrating advances in epidemiology, pathogenesis, immunity, diagnostics, and control. The pathogen is globally endemic, with transmission driven mainly by di...

Neuropeptide Y—Graphene Oxide Complexes Inhibit Amygdala NPY‐Receptor Expressing Glutamatergic Pathways and Selectively Remove Aversive Memory In Vivo

Therapeutic needs to modulate brain circuits highlight graphene-based materials (GBMs) as an emerging tool to engineer specific interventions to treat neuro-diseases. In this context, graphene oxide (GO) nanosheets offer new drug delivery strategies to reach neural cells and sign...